$-0.09
(Market cap
$20 Mln
Recently Viewed
Clear AllMarket cap
$20 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.4
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
8,616,010
CFO
$-120.93 Mln
EBITDA
$-168.50 Mln
Net Profit
$-166.82 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
| 7.4 | 7.4 | -33.7 | -38.4 | -80.2 | -75.1 | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
| -52.4 | -35.6 | -98.0 | -76.8 | -40.0 | -56.8 | -89.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
|
1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 |
| 131.8 | 28,613.9 | 0.0 | -1,131.3 | -- | -58.1 | -- | 17.5 |
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality... as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. Read more
CEO, President, Principal Executive & Director
Mr. Hyung-Heon Kim
CEO, President, Principal Executive & Director
Mr. Hyung-Heon Kim
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neurobo Pharmaceuticals Inc (NRBO) is $1.89 (NASDAQ) as of 29-Jan-2025 09:30 EDT. Neurobo Pharmaceuticals Inc (NRBO) has given a return of -80.17% in the last 3 years.
Since, TTM earnings of Neurobo Pharmaceuticals Inc (NRBO) is negative, P/E ratio is not available.
The P/B ratio of Neurobo Pharmaceuticals Inc (NRBO) is 1.32 times as on 29-Jan-2025, a 70 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Neurobo Pharmaceuticals Inc (NRBO) are Rs -- and Rs -- as of 27-Apr-2026.
Neurobo Pharmaceuticals Inc (NRBO) has a market capitalisation of $ 20 Mln as on 29-Jan-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Neurobo Pharmaceuticals Inc (NRBO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.